Shares of NovoCure (NVCR) have risen over fivefold since introducing this medical device story to readers in 2016. The stock price is up over 50% since my December update piece suggested investors take advantage of a "solid buying opportunity" caused by flat prescription growth in Q3.
Figure 1: Daily advanced chart (source: Finviz)
Racking Up Another Approval
Today's news was somewhat expected yet welcome nevertheless, as the company announced FDA approval of its NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant